Last reviewed · How we verify
Insulin Degludec U100
At a glance
| Generic name | Insulin Degludec U100 |
|---|---|
| Also known as | tresiba |
| Sponsor | Weill Cornell Medical College in Qatar |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IDegLira HIGH Trial (PHASE3)
- Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (PHASE4)
- Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes (PHASE4)
- A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (PHASE4)
- Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors (PHASE4)
- Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Degludec U100 CI brief — competitive landscape report
- Insulin Degludec U100 updates RSS · CI watch RSS
- Weill Cornell Medical College in Qatar portfolio CI